



CORRECTION

Correction to: Practical Approaches to Treating Obesity: Patient and Healthcare Professional Perspectives

Donal O'Shea · Scott Kahan · Lorna Lennon · Cathy Breen

Published online: June 3, 2021
© Springer Healthcare Ltd., part of Springer Nature 2021

Correction to: Adv Ther
<https://doi.org/10.1007/s12325-021-01748-0>

In Table 2 of the original article the 'Route of administration' for 'Semaglutide' was published

incorrectly. The route of administration was published as 'Oral'. The correct route of administration should be subcutaneous. The correct Table 2 is given below:

Table 2 Summary of dosing regimens of available and investigational weight management pharmacotherapies

| | Route of administration | Dose |
|---------------------------------|-------------------------|--|
| Orlistat [46–48] | Oral | Prescription: 120 mg three times daily OTC: 60 mg three times daily |
| Phentermine/topiramate [49, 50] | Oral | Up to 15 mg/92 mg daily |
| Liraglutide [51, 52] | Subcutaneous | 3 mg daily |
| Naltrexone/bupropion [53, 54] | Oral | Up to 32 mg/360 mg daily |
| Semaglutide ^a [55] | Subcutaneous | 2.4 mg daily |

Weight management agents should always be used in conjunction with appropriate behavioural interventions.

^a Semaglutide is an investigational product and has not been approved by the FDA or EMA at the time of writing.

The original article can be found online at <https://doi.org/10.1007/s12325-021-01748-0>.

The original article has been corrected.

D. O'Shea
University College Dublin, Dublin, Ireland

S. Kahan
George Washington University, Washington, D.C., USA

C. Breen (✉)
St Columcille's Hospital, Dublin, Ireland
e-mail: cathy.breen@hse.ie